Krystal Biotech Receives Permanent J-code (J3401) for VYJUVEK®
January 04, 2024 07:00 ET
|
Krystal Biotech, Inc.
PITTSBURGH, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company focused on the discovery, development and...
Krystal Biotech Receives Orphan Drug Designation from the Japanese MHLW for Beremagene Geperpavec-svdt (B-VEC)
December 19, 2023 07:00 ET
|
Krystal Biotech, Inc.
PITTSBURGH, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company focused on the discovery, development and...
Krystal Biotech Announces EMA Validation of Marketing Authorization Application for VYJUVEK for the Treatment of Dystrophic Epidermolysis Bullosa
November 27, 2023 07:00 ET
|
Krystal Biotech, Inc.
If approved, ~3,000 people with DEB in the European Union could receive VYJUVEK to treat the underlying cause of the disease for the first timeVYJUVEK received Orphan Drug Designation and PRIME...
Krystal Biotech to Present at the Stifel 2023 Healthcare Conference
November 09, 2023 07:00 ET
|
Krystal Biotech, Inc.
PITTSBURGH, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company focused on the discovery, development and...
Krystal Biotech Announces Third Quarter 2023 Financial Results and Provides Business Update
November 06, 2023 07:00 ET
|
Krystal Biotech, Inc.
• 284 VYJUVEK Patient Start Forms and $8.6 million in VYJUVEK U.S. net product revenue as of the end of the third quarter • Cohort 1 completed in Phase 1 clinical trial of KB407 for the treatment...
Krystal Biotech to Report Third Quarter 2023 Financial Results on November 6, 2023
October 30, 2023 07:00 ET
|
Krystal Biotech, Inc.
PITTSBURGH, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company focused on the discovery, development and...
Krystal Biotech to Present at the Chardan 7th Annual Genetic Medicines Conference
September 28, 2023 07:00 ET
|
Krystal Biotech, Inc.
PITTSBURGH, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company focused on the discovery, development and...
Krystal Biotech Announces FDA Clearance of Investigational New Drug Application for KB408 for the Treatment of Type 1 Alpha-1 Antitrypsin Deficiency
September 21, 2023 09:00 ET
|
Krystal Biotech, Inc.
• Orphan Drug Designation Granted to KB408 PITTSBURGH, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company...
Krystal Biotech to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
September 07, 2023 07:00 ET
|
Krystal Biotech, Inc.
PITTSBURGH, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company focused on the discovery, development and...
Krystal Biotech Announces Orphan Drug Designation Granted to KB408 for the Treatment of Alpha-1 Antitrypsin Deficiency
September 05, 2023 07:00 ET
|
Krystal Biotech, Inc.
KB408 IND filed on August 15, 2023 PITTSBURGH, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company focused on the...